Your institution may have access to this item. Find your institution then sign in to continue.
Title
Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.
Authors
Scagliotti, G V; Kosmidis, P; de Marinis, F; Schreurs, A J M; Albert, I; Engel-Riedel, W; Schallier, D; Barbera, S; Kuo, H-P; Sallo, V; Perez, J R; Manegold, C
Abstract
Bone metastases are common in patients with advanced non-small-cell lung cancer (NSCLC) and can have devastating consequences. Preventing or delaying bone metastases may improve outcomes.
Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 8, p2082